Hospital
GPCH, LLC
GPCH, LLC was paid $2.46M by Medicaid between Oct 2020 and Dec 2024, across 48 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 52% of everything it billed.
33Billing provider infoGPCH, LLC
BORGER, TX 79007
BORGER, TX 79007
33aNPI1841497153assigned 06/29/2007
33bProvider typeCritical Access Hospital
28Total paid$2.46M
24GClaims29,047
24DCodes billed48
24AFirst – last monthOct 2020 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Texas
Rank by total paid#5 of 47
Median peer was paid$170K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 676 | $25K | |
| 2021 | 7,610 | $881K | |
| 2022 | 7,511 | $595K | |
| 2023 | 8,403 | $614K | |
| 2024incomplete | 4,847 | $349K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 52% | 2,109 | 2,050 | $1.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 1,382 | 1,335 | $459K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 364 | 352 | $287K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.1% | 3,629 | 2,787 | $126K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 1,855 | 1,802 | $38K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 3,221 | 2,859 | $34K |
| 80053 | Comprehensive metabolic panel | 1.3% | 2,262 | 2,029 | $33K |
| 87070 | 1.1% | 1,427 | 1,379 | $27K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 1.0% | 508 | 392 | $25K |
| 81002 | <1% | 3,648 | 2,373 | $17K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 768 | 500 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,959 | 3,316 | $12K |
36 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 782 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 67 | $9K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 313 | $8K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 59 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 210 | $7K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 191 | $7K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 111 | $7K |
| 84436 | <1% | 206 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 102 | $5K |
| 80306 | <1% | 162 | $4K | |
| 81001 | <1% | 933 | $3K | |
| 99460 | <1% | 42 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12 | $2K |
| 86701 | <1% | 154 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 14 | $2K |
| 87634 | <1% | 15 | $2K | |
| 99462 | <1% | 41 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 45 | $1K |
| 87807 | <1% | 52 | $957.10 | |
| 80061 | Lipid panel | <1% | 67 | $940.42 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16 | $667.95 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 15 | $647.39 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 15 | $636.35 |
| 81025 | <1% | 40 | $594.65 | |
| 87186 | <1% | 37 | $552.44 | |
| 87077 | <1% | 32 | $419.30 | |
| 85730 | <1% | 28 | $326.51 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 12 | $316.38 |
| 83655 | <1% | 12 | $280.09 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25 | $244.31 |
| 85610 | <1% | 28 | $235.49 | |
| 84703 | <1% | 28 | $205.64 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $93.84 |
| 86140 | <1% | 12 | $75.22 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDERSON, MELODY (INTERIM CEO)